Subtopic Deep Dive
Dihydromyricetin Anticancer Properties
Research Guide
What is Dihydromyricetin Anticancer Properties?
Dihydromyricetin (DHM), also known as ampelopsin, exhibits anticancer properties by inducing apoptosis and inhibiting proliferation in cancer cell lines through ROS modulation and PI3K/Akt pathway targeting.
DHM from Ampelopsis grossedentata shows activity against breast, prostate, and hepatocellular carcinoma cells. Key studies demonstrate ROS reduction leading to apoptosis (Liu et al., 2014, 89 citations) and ER stress in breast cancer (Zhou et al., 2014, 107 citations). Over 10 papers since 2012 explore its mechanisms, with Zhang et al. (2018, 192 citations) reviewing pharmacological effects including anticancer potential.
Why It Matters
DHM's ability to reduce ROS and induce apoptosis in hepatocellular carcinoma cells positions it as a candidate for adjuvant oncology therapies (Liu et al., 2014). In breast cancer models, DHM triggers ER stress and growth inhibition, suggesting synergy with chemotherapeutics (Zhou et al., 2014). Prostate cancer studies show metastasis suppression, supporting plant-derived agents in hormone-sensitive tumors (Ni et al., 2012). These effects highlight DHM's potential to lower chemotherapy doses and side effects.
Key Research Challenges
Translating in vitro apoptosis
Most evidence comes from cell lines like PC12 and breast cancer, lacking robust in vivo tumor models (Zhou et al., 2014; Liu et al., 2014). Limited animal data hinders clinical translation. Human trials absent.
Mechanistic pathway specificity
DHM targets ROS, AMPK/GLUT4, and ER stress, but PI3K/Akt interactions underexplored (Jiang et al., 2014; Zhang et al., 2018). Overlapping antioxidant effects confuse cancer-specific signals. Needs targeted inhibitors.
Synergy with chemotherapeutics
Synergistic potential noted but unquantified across cancer types (Zhang et al., 2018). Dose-response in combinations missing. Clinical safety profiles undefined.
Essential Papers
Role of Antioxidants and Natural Products in Inflammation
Palanisamy Arulselvan, Masoumeh Tangestani Fard, Woan Sean Tan et al. · 2016 · Oxidative Medicine and Cellular Longevity · 949 citations
Inflammation is a comprehensive array of physiological response to a foreign organism, including human pathogens, dust particles, and viruses. Inflammations are mainly divided into acute and chroni...
Recent Update on the Pharmacological Effects and Mechanisms of Dihydromyricetin
Jingyao Zhang, Yun Chen, Huiqin Luo et al. · 2018 · Frontiers in Pharmacology · 192 citations
As the most abundant natural flavonoid in rattan tea, dihydromyricetin (DMY) has shown a wide range of pharmacological effects. In addition to the general characteristics of flavonoids, DMY has the...
Alcohol use disorders and current pharmacological therapies: the role of GABAA receptors
Jing Liang, Richard W. Olsen · 2014 · Acta Pharmacologica Sinica · 152 citations
Ampelopsin Induces Cell Growth Inhibition and Apoptosis in Breast Cancer Cells through ROS Generation and Endoplasmic Reticulum Stress Pathway
Yong Zhou, Furong Shu, Xinyu Liang et al. · 2014 · PLoS ONE · 107 citations
Ampelopsin (AMP), a major bioactive constituent of Ampelopsis grossedentata, exerts a number of biological effects. In this study, we investigated its anti-cancer activity in human breast cancer ce...
Ampelopsin attenuates brain aging of D-gal-induced rats through miR-34a-mediated SIRT1/mTOR signal pathway
Xianjuan Kou, Xingran Liu, Xianbing Chen et al. · 2016 · Oncotarget · 101 citations
The underlying molecular mechanisms for aging-related neurodegenerative diseases such as Alzheimer's disease (AD) are not fully understood. Currently, growing evidences have revealed that microRNAs...
The Versatile Effects of Dihydromyricetin in Health
LI Hong-liang, Qisheng Li, Zhaowen Liu et al. · 2017 · Evidence-based Complementary and Alternative Medicine · 98 citations
Dihydromyricetin is a flavonoid isolated from Ampelopsis grossedentata , which is traditionally used in China. Dihydromyricetin exhibits health‐benefiting activities with minimum adverse effects. D...
Dihydromyricetin protects neurons in an MPTP-induced model of Parkinson's disease by suppressing glycogen synthase kinase-3 beta activity
Zhaoxiang Ren, Yafei Zhao, Ting Cao et al. · 2016 · Acta Pharmacologica Sinica · 97 citations
Reading Guide
Foundational Papers
Start with Zhou et al. (2014, 107 citations) for breast cancer apoptosis via ER stress/ROS, Liu et al. (2014, 89 citations) for HCC mechanisms, Ni et al. (2012, 79 citations) for prostate metastasis inhibition—these establish core in vitro evidence.
Recent Advances
Zhang et al. (2018, 192 citations) updates mechanisms; Arulselvan et al. (2016, 949 citations) contextualizes antioxidants in inflammation-cancer links relevant to DHM.
Core Methods
MTT/proliferation assays, ROS detection (DCFH-DA), apoptosis (Annexin V/PI flow cytometry), Western blots for cleaved caspase-3, p-Akt, ER markers; some mouse xenograft models (Zhou et al., 2014; Liu et al., 2014).
How PapersFlow Helps You Research Dihydromyricetin Anticancer Properties
Discover & Search
Research Agent uses searchPapers('dihydromyricetin anticancer OR ampelopsin apoptosis') to find 10+ core papers like Liu et al. (2014), then citationGraph reveals forward citations on ROS-apoptosis links, and findSimilarPapers expands to synergy studies from Zhou et al. (2014). exaSearch queries 'DHM PI3K/Akt cancer cell lines' for niche results.
Analyze & Verify
Analysis Agent applies readPaperContent on Liu et al. (2014) to extract ROS reduction data, verifyResponse with CoVe checks claims against Zhou et al. (2014), and runPythonAnalysis plots dose-response curves from extracted IC50 values using matplotlib for statistical verification. GRADE grading scores evidence as moderate due to in vitro focus.
Synthesize & Write
Synthesis Agent detects gaps like in vivo validation via contradiction flagging across papers, then Writing Agent uses latexEditText for methods sections, latexSyncCitations integrates 10+ refs, and latexCompile generates polished reviews with exportMermaid for PI3K/Akt pathway diagrams.
Use Cases
"Extract and plot IC50 values for DHM apoptosis in cancer cell lines from top papers."
Research Agent → searchPapers → Analysis Agent → readPaperContent (Liu et al. 2014, Zhou et al. 2014) → runPythonAnalysis (pandas plot IC50 vs cell line) → matplotlib figure of dose-responses.
"Write LaTeX review on DHM ROS mechanisms in hepatocellular carcinoma."
Synthesis Agent → gap detection → Writing Agent → latexEditText (intro+results) → latexSyncCitations (9 papers) → latexCompile → PDF with pathway Mermaid diagram.
"Find code for DHM simulation models or analysis scripts."
Research Agent → paperExtractUrls (Jiang et al. 2014) → paperFindGithubRepo → githubRepoInspect → runPythonAnalysis on shared AMPK/GLUT4 scripts → verified simulation outputs.
Automated Workflows
Deep Research workflow scans 50+ papers via searchPapers on 'dihydromyricetin cancer', structures report with GRADE-scored sections on apoptosis mechanisms from Liu et al. (2014). DeepScan's 7-step chain verifies ROS claims: readPaperContent → CoVe → runPythonAnalysis on data extracts. Theorizer generates hypotheses on DHM-chemotherapy synergy from Zhang et al. (2018) patterns.
Frequently Asked Questions
What defines dihydromyricetin anticancer properties?
DHM induces apoptosis via ROS reduction in hepatocellular carcinoma (Liu et al., 2014) and ER stress in breast cancer cells (Zhou et al., 2014).
What are main methods in DHM cancer studies?
Cell line assays measure proliferation/apoptosis with MTT, flow cytometry for ROS/Annexin V; Western blots target PI3K/Akt, ER stress markers (Zhou et al., 2014; Liu et al., 2014).
What are key papers on DHM anticancer effects?
Zhou et al. (2014, 107 citations) on breast cancer apoptosis; Liu et al. (2014, 89 citations) on HCC ROS; Zhang et al. (2018, 192 citations) reviews mechanisms.
What open problems exist?
Lack in vivo models, undefined PI3K/Akt specificity, untested chemo-synergies require animal trials and pathway inhibitors (Zhang et al., 2018).
Research Medicinal plant effects and applications with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Dihydromyricetin Anticancer Properties with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers